Detalles de la búsqueda
1.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist;
2024 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38394384
2.
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data.
J Urol;
205(2): 554-560, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33090917
3.
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
Prostate;
80(14): 1159-1176, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32779781
4.
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
J Urol;
203(4): 743-750, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31580749
5.
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
Cancer;
125(23): 4172-4180, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31483485
6.
A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III).
J Urol;
201(4): 682-692, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30077557
7.
Germline testing for prostate cancer: community urology perspective.
Can J Urol;
26(5 Suppl 2): 50-51, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31629433
8.
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.
BMC Urol;
18(1): 84, 2018 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30285696
9.
Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.
BMC Urol;
18(1): 77, 2018 Sep 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30189902
10.
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.
Cancer;
126(12): 2935-2937, 2020 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32154908
11.
Avoiding obsolescence in advanced prostate cancer management: a guide for urologists.
BJU Int;
115(2): 188-97, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25756134
12.
Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer.
Urol Oncol;
41(11): 454.e9-454.e16, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37734979
13.
Obesity, body composition, and prostate cancer.
BMC Cancer;
12: 23, 2012 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-22257467
14.
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
Prostate Cancer Prostatic Dis;
25(2): 363-365, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34621011
15.
Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer.
J Urol;
185(6): 2102-7, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21496850
16.
Development and evaluation of the MiCheck test for aggressive prostate cancer.
Urol Oncol;
38(8): 683.e11-683.e18, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32305266
17.
A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial.
Urol Oncol;
38(8): 683.e1-683.e10, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32360170
18.
The Effect of Local Antibiogram-based Augmented Antibiotic Prophylaxis on Infection-related Complications Following Prostate Biopsy.
Rev Urol;
21(2-3): 93-101, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31768136
19.
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.
Prostate Cancer Prostatic Dis;
22(4): 588-592, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30980027
20.
Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker.
Oncotarget;
9(32): 22359-22367, 2018 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-29854284